Clinical Trial Update: Study of Add-on Ambrisentan Therapy to Background Phosphodiesterase Type-5 Inhibitor (PDE5i) Therapy in Pulmonary Arterial Hypertension (ATHENA-1) [Phase 4]

View source ↗

Summary

Phase 4 ATHENA-1 evaluated adding ambrisentan to background PDE5 inhibitor therapy in pulmonary arterial hypertension; results were posted in July 2012.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pulmonary Arterial Hypertension

Drugs mentioned

• Ambrisentan (Ambrisentan)
• PDE5 inhibitor (background therapy)

Snippet

Sponsor: Gilead Sciences | Conditions: Pulmonary Arterial Hypertension | Phase 4 | Status: COMPLETED | Results posted: 2012-07-30